tbuckley/cabot-search huggingface dataset:
571P Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Authors: M. Carullo, C. Antoniotti, C. Ahn, T. Lee, V. Angerilli, M. Ambrosini, D. Rossini, F. Schietroma, S. Lonardi, S. Tamberi, F. Ghelardi, M. Seo, A. Righetto, V. Conca, G. Vetere, S. Shin, C. Ugolini, C-Y. Ock, None M. fassan, C. Cremolini
Journal: Annals of Oncology (2023)
596P Comparison of neoadjuvant chemoradiotherapy with CAPEOX versus single-agent capecitabine in high-risk locally advanced rectal cancer: Long-term results from a multicenter randomized controlled trial (MONT-R)
Authors: G. Lin, J. Zhou, G. Li, Y. Xiao, W. Jia, Q. Liu, B. Wu, A. Wu, J. Han, Z. Wang, H. Yao, Z. Shen, A. Li, Z. Zhang
Journal: Annals of Oncology (2023)
574P Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Authors: M. Fakih, J. Ye, C. Wang, C. Egelston, M. Huang, J. Mercer, M.A. Thompson, J. Gong
Journal: Annals of Oncology (2023)
10P Cancer cells induce intracellular gap formation in sinusoidal endothelial cells to produce liver metastasis through pro-inflammatory paracrine mechanisms
Authors: H.H. Truong, M. Sato-Mátubara, T. Matsubara, H. Yuasa, T. Le Thi Thanh, J. Gracia-Sancho, N. Kawada
Journal: Annals of Oncology (2023)
24P Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Authors: A. Frolova, T.S. Gerashchenko, M. Patysheva, A.A. Fedorov, O. Bragina, E. Garbukov, N. Cherdyntseva, V.Y. Korobeynikov
Journal: Annals of Oncology (2023)
35P SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Authors: S. Patra, M. Pothuganti, V. Sankeshi, G. K, H. Pathange, R. S, K. Soumyajit, S. Viswanadha
Journal: Annals of Oncology (2023)
589P Impact of landmark point selection on molecular residual disease detection in stage I-IV resectable colorectal cancer
Authors: D. Cao, C. Li, F. Wang, R. Zhang, X. Wu, L. Li, Z. Lu, Z. Pan, J-Z. Lin, M. Wu, Y. Liu, G. Lv, F. Qiu, Y. Liu, H. Xin, G. Chen
Journal: Annals of Oncology (2023)
19P Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Authors: Y. Morera, M. Bequet-Romero, F. Hernández-Bernal, I. González-Moya, K-H. Selman-Housein, C. Canaan-Haden, J. Sanchez-Ramirez, Y. Martín-Bauta, A. de la Torre-Santos, M. Ayala
Journal: Annals of Oncology (2023)
CN66 Cancer symptom clusters, nutritional status and quality of life of patients with cancer undergoing outpatient chemotherapy
Authors: L.C. Lopes-Júnior, K.Z. Nunes, R.M.M. Pessanha, L.C.B.S. Neto, K.C.G. Viana, J. Grassi, W.R. Grippa, R.J.G.S. Silva, J.A.C. Marcarini, K.N. Gomes, A.B. Lopes
Journal: Annals of Oncology (2023)
CN72 Symptom burden, quality of life and emotional status of patients with advanced lung cancer seen at the functional lung unit
Authors: Brao Perez, M. Arellano, C. Lasmarias, S. Padrones Sanchez, E. Nadal, R. Palmero Sanchez, M. Jove Casulleras, J. Brenes Castro, M.A. Mosteiro Lamas, J. Saldaña Cañada, R.A. Portolés
Journal: Annals of Oncology (2023)
578P Tissue-resident microbiota characterization in colorectal cancer metastases
Authors: P. Stevens, V. Llorens-Rico, E. Benidovskaya, P. Baldin, L. Coubeau, V. Lacroix, D. Leonard, R. Bachmann, L. Craciun, S. Gofflot, F. George, F. Sandras, J. Sadones, M. Buys, J. Raes, M. van den Eynde
Journal: Annals of Oncology (2023)
597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Authors: M. Weiser, Q. Shi, G.J. Chang, L. Hakki, J. Goldberg, R. Auer, M. Gollub, L. Saltz, B.L. Musher, T. Al baghdadi, J. Farma, T. George, B. Colgrove, G. Nelson, E.M. O'Reilly, A. Shergill, J. Meyerhardt, H. Mamon, D. Schrag
Journal: Annals of Oncology (2023)
602P Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Authors: D. Bugano Diniz Gomes, V.M. Santos, A. Campos Bragagnoli, O. Barbosa Neto, I.T. Carvalho, J. Karassawa Helito, C.D. Ortega, C. Franco Tridente, M. Novaes Figueiredo de Araújo, R.V. Pandini, V.E. Seid, A.S. Portilho, J.M. Melo, P. Blasi, A. Buosso, F. Rolla, G. Schettino, S.E.A. Araujo
Journal: Annals of Oncology (2023)
2326P Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Authors: M. Ghidini, J.C. Hahne, C. Senti, G. Tomasello, M. Ratti, T. Heide, O. Garrone, A. Cortellini, R. Passalacqua, N. Valeri
Journal: Annals of Oncology (2023)
594P The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Authors: N. Izawa, T. Kudo, S. Yuki, M. Nakamura, D. Manaka, Y. Kumekawa, T. Mine, T. Okuno, H. Oda, T. Sagawa, T. Kawai, T. Shingai, M. Kotaka, K. Kobayashi, Y. Kagawa, H. Satake, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa
Journal: Annals of Oncology (2023)
588P PLCRC-PROVENC3 study: Prognostic value of post-surgery liquid biopsy circulating tumor DNA in stage III colon cancer patients
Authors: C. Rubio-Alarcón, I.A. Franken, S.C.M.W. van Nassau, S. Schraa, L. Meiqari, S. Ketelaars, V. Velculescu, S. Angiuoli, A. Georgiadis, D. Riley, C. Greco, D. Van Den Broek, C.J.A. Punt, V. Coupé, M. Koopman, J.M.L. Roodhart, G. Meijer, M. Sausen, G.R. Vink, R. Fijneman
Journal: Annals of Oncology (2023)
41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models
Authors: S. Zhang, D. Mills, J.Y. Kim, N. Knudsen, J. Nelson, Y. Buechler, L. Skidmore
Journal: Annals of Oncology (2023)
49P Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Authors: A.J.A. de Freitas, C.R. Nunes, R.L. Causin, S. Calfa, M.A. de Oliveira, C. de Pádua Souza, M.M.C. Marques
Journal: Annals of Oncology (2023)
26P Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Authors: M. White, T. Lannagan, L. McGarry, L. Carlin, M. Mills, A.S. Yazgili, R. Ridgway, R. Jackstadt, A.D. Campbell, R.H. Wilson, O.J. Sansom
Journal: Annals of Oncology (2023)
550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
Authors: R-H. Xu, Y. Xu, D. Yan, P. Munster, D. Ruan, Y. Deng, H. Pan, C.R. Underhill, G. Richardson, I. Nordman, K-W. Lee, S. Wei, X. Li, J. Shan, G. Han, S. Henderson, X. Xie, Z. Xiang, Z. Shi, L. Zhang
Journal: Annals of Oncology (2023)
30P Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Authors: M. Macia-Guardado, M. Ertl, V. Lutz, E. Ebner, E. Koncina, S. Stang, M. Hengstschläger, E. Letellier, J. Schüler, H. Dolznig
Journal: Annals of Oncology (2023)
CN57 Patients, informal caregivers and healthcare professionals experience in adoptive cell therapies: An experience-based co-design study (EBCD-ACT)
Authors: N. Canova, N. Graber, T. Corbière, F. Bosisio, A. Kaufmann, D. Bryant-Lukosius, M. Eicher, S. Colomer-Lahiguera
Journal: Annals of Oncology (2023)
25P Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Authors: T. Yamada, K. Morimoto, S. Hirai, Y. Katayama, K. Kunimasa, T. Sasaki, M. Nishida, S. Watanabe, S. Shiotsu, H. Uehara, K. Takayama
Journal: Annals of Oncology (2023)
593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts)
Authors: J. Loh, J. Choo, K. Sooi, P. Low, C.S. Ang, R. Sundar, R.J. Walsh, S. Wijaya, J.L. Low, S. Hsing, S. Jain, C.E. Chee
Journal: Annals of Oncology (2023)
554MO Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial
Authors: Y. Li, D. Wang, C. Ren, S-S. Li, W. Pat Fong, X. Wu, J. Xiao, Y. Yuan, B-K. Li, P-R. Ding, Z. Wang, F. Wang, Z. Pan, G. Chen, X-Z. Wang, L-Y. Wang, T. Chen, T. Liu, Y. Yuan, R-H. Xu
Journal: Annals of Oncology (2023)
14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Authors: M.A. Galindo Campos, M. Hardy-Werbin, J. Gibert, A. Ríos-Hoyo, A. Rossell, S. Gonzalez, P. Rocha, R. Del Rey-Vergara, A. Rovira, E. Arriola
Journal: Annals of Oncology (2023)
7P Engineered salmonella blocks cancer metastasis by activating NK cells in an IFN-γ-dependent manner
Authors: J. Huang
Journal: Annals of Oncology (2023)

Metastasis accounts for 90% of cancer related deaths and blocking of metastatic cascade has critical clinical impact. However, the clinical drug development for cancer treatment, including cancer immunotherapies, is evaluated largely depending on their ability to cause tumour shrinkage and ignores the effect on metastasis as it has proven challenging to target. Therefore, there is an urgent need for novel therapeutic strategies and agents targeting metastasis. Using an attenuated Salmonella typhimurium strain YB1 engineered by our lab, we have found a potent suppressive effect of attenuated Salmonella on cancer metastasis, regardless of cancer types and genetic background, by evoking strong anti-metastatic immune response. Mutant mice and antibody-mediated cell depletion were used to identify the host genetic and cellular requirement for the bacterial supression of cancer cell metastasis. CyTOF (mass cytometry or cytometry by time of flight) was used to investigate the the innate immune responses after Salmonella treatment. Our studies showed that suppression of cancer metastasis by attenuated Salmonella only requires the innate immune response. Among the many induced cytokines, IFN-γ was identified as an indispensable factor for inhibiting cancer metastasis. CyTOF and antibody-mediated cell depletion analysis of the innate immune responses after Salmonella treatment, revealed that NK cells are the major factor involved in Salmonella-provoked metastasis suppression. We found that IFN-γ was mainly produced by NK cells during early Salmonella infection, and in turn, IFN-γ promoted the accumulation, activation and cytotoxicity of NK cells. The IFN-γ-dependent NK cells directly eliminated newly accumulated cancer cells in the lung to block the cancer metastasis cascade in response to the Salmonella treatment.
551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER
Authors: J.H. Strickler, A. Cercek, K. Ng, S. Siena, T. André, E. Van Cutsem, C. Wu, A.S. Paulson, J. Hubbard, A.L. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H.J. Lenz, K.K. Ciombor, M.E. Elez Fernandez, M. Stecher, P. Cronin, M. Bieda, T. Bekaii-Saab
Journal: Annals of Oncology (2023)
557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Authors: C. Coutzac, F. Bigot, D. Vansteene, M. Dos Santos, F. Ghiringhelli, B. You, A. Lambert, C.A. Gomez-Roca, C. Abdeddaim, C. Neuzillet, E. Jeannot, E. Guerini Rocco, G. Frige, L. Mazzarella, C. Dupain, M. Kamal, F. Legrand, M. Jimenez, T. Filleron, C. Le Tourneau
Journal: Annals of Oncology (2023)
2341P Novel therapeutic opportunities in metaplastic breast cancer
Authors: F. Pareja, A. Gazzo, H. Dopeso, D. Brown, P. Selenica, Y. Zhu, J. Blanco Heredia, L. Gusain, X. Pei, A. Marra, G. Montagna, N. Abuhadra, H. Wen, E. Brogi, N. Riaz, S. Chandarlapaty, M. Scaltriti, S. Powell, B. Weigelt, J.S. Reis-Filho
Journal: Annals of Oncology (2023)
564P A large-scale real-world study for colorectal cancer screening
Authors: S. Liu, Y. Wang, D. Zhuo, J. Peng, R. Jiang, C. Duan, F. Liu, H. Zhang, X. Tian, X. Ding, M. Zhang, D. Cao, Y. Liu, Y. Wang, Z. Shi
Journal: Annals of Oncology (2023)
1587P Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Authors: T-H. Kim, E. Lee, H.W. Lee, M.S. Ahn, Y.W. Choi, M. Kwon, S.Y. Kang, J-H. Choi
Journal: Annals of Oncology (2023)
CN70 Out of hours symptom triage and supportive care
Authors: K. Mckendry, N. Pierce, A. Smullen, K. Skehan, N. Termanini, D. Coyle, P. Francis, E. Buggy, M. Saviour, S. Meagher, E. Babikir, O. Kestell, A. Comiskey, E. Sinagoga, O.S. Breathnach, K. Egan, None F.E. barrett, L. Keogh, L. French
Journal: Annals of Oncology (2023)
13P Disrupting the immunosuppressive tumor microenvironment using genetically engineered macrophages for triple-negative breast cancer therapy
Authors: S. Traxel, C. Beerli, F. Schmidt, V. Dinh-Van, R.F. Speck, S. Bredl
Journal: Annals of Oncology (2023)

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and accounts for 40% of breast cancer deaths. Currently, surgery and chemotherapy are standard therapy in TNBC, whereas immunotherapies often fail due to a cold tumor microenvironment (TME), which is mainly generated by tumor associated macrophages (TAMs). Importantly, immunosuppressive M2-like TAMs are associated with worse outcome in TNBC patients. Cytokines like IL-10 and TGFβ induce M2-like TAMs, which inhibit the adaptive immune response and promote tumor growth, migration, and vascularization. In contrast, M1-like macrophages induce an anti-tumor immune response and tumor cell death. Thus, we aim to develop an adoptive cell therapy employing macrophages that are polarized towards a M1-like phenotype by the immunosuppressive cytokines, which will generate an inflamed TME. To achieve M1 polarization in a M2-inducing TME, we genetically modified macrophages to express a chimeric cytokine receptor (ChCR), which will induce an M1 signaling upon stimulation with M2 inducing cytokines. Here, we evaluated two ChCR variants activated by IL-10 and TGFβ, respectively. We transduced monocytes to express the ChCR using lentiviruses. Upon differentiation to macrophages, we assessed M1 polarization by analyzing surface marker expression and the secretome. Moreover, we assessed their effect on TNBC cell line viability. We could successfully transduce macrophages at 80% and confirmed ChCR expression and M1 signaling. Furthermore, we could show that stimulation of ChCR macrophages by IL-10 or TGFβ switches them towards an M1-like phenotype, as analyzed by surface marker expression and IP-10 secretion. Moreover, we found that the viability of TNBC cell lines was reduced upon treatment with supernatants of TGFβ or IL-10 stimulated ChCR macrophages. We could show that we can engineer macrophages to switch towards an M1-like phenotype in an M2-inducing environment. Thus, ChCR macrophages represent a promising strategy to disrupt the immunosuppressive TME. Currently, we are assessing the effect of ChCR macrophages on immune activation in vitro and their phenotype in TNBC co-cultures.
1531P Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
Authors: Y-G. Hong, X. Meng, X. Yang, Z-Y. Zhang, J. Xia, Y-F. Chen, T. Wu, Z. Shan, Q. Fan, F. Wang
Journal: Annals of Oncology (2023)
2317P Mutational landscape and therapeutic implications in squamous cell carcinomas
Authors: L. Belcaid, M. Eriksen, L. Robinson, C. Federspiel Secher, M. Hoejgaard, I. Spanggaard, K.G. Daugaard, J. Friborg, P.M. Mau-Sorensen, J. Weischenfeldt, U. Lassen, C. Yde, K. Rohrberg
Journal: Annals of Oncology (2023)
1533P Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
Authors: M. Sun, D.R. Spigel, Y-J. Lee, H. Yoon, Y. Liu, E. Ahern, S. Harris, G-W. Lee, D. Yan, J. Chen, H-S. Shiah, T. Deng, H. Zheng, W. Tan, Z. Zhou, R. Wang, Y. Ba
Journal: Annals of Oncology (2023)
2330P Pre-test prediction of multiple druggable mutations based on H&amp;E image artificial intelligence (AI) analysis may enable more efficient clinical workflow for treatment decisions in non-small cell lung cancer (NSCLC)
Authors: J. Lee, S. Park, S-H. Lee, Y-L. Choi, Y-D. Choi, M-G. Noh, J. Park, S. Shin, T. Lee, H. Song, J. Ro, J. Moon, S. Kim, C. Ahn, S. Pereira, D. Yoo, C-Y. Ock
Journal: Annals of Oncology (2023)
2324P Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Authors: A. Puyalto, M. Rodríguez-Remírez, I. López, M. Olmedo López-Frías, A. Vilalta, I. Macaya, C. Welch, S. Vicent, A. Calvo, D. Ajona, I. Gil Bazo
Journal: Annals of Oncology (2023)
104P Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
Authors: H. Jeong, K-P. Kim, J.H. Jeong, D.W. Hwang, J.H. Lee, K-H. Kim, D-B. Moon, M.A. Lee, S.J. Park, H. Chon, J-H. Park, J.S. Lee, B-Y. Ryoo, C. Yoo
Journal: Annals of Oncology (2023)
12P Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Authors: C. Schuberth-Wagner, I. Giese, M. Kist, N. Vashist, S. Genßler, B. Haack, J. Weigandt, M. Auer, J. Wischhusen, K. Klar, E. Leo, M. Haake
Journal: Annals of Oncology (2023)
126P Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
Authors: A. Lacasta, T. Macarulla, A.O. Castillo Trujillo, M.M. Herrera Juarez, A.J. Munoz Martin, R. Vidal Tocino, C. Fabregat, R.M. Rodríguez, M. Lobo de Mena, P. Peinado, M. Granja Ortega, A. Fernandez Montes, B. Grana Suarez, E. Martinez de Castro, J. Gallego Plazas, R. Vera, I.C. Ales Diaz, I. Ghanem, I. Gallego Jimenez, E. Aranda Aguilar
Journal: Annals of Oncology (2023)
2312P SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Authors: A. Bonelli, M.L. Canale, I. Bisceglia, G. Palma, A. Luciano, F. Bruzzese, F. Russo, V. Giordano, C. Maurea, A. Paccone, M. Iovine, F. Florio, N. Maurea, V. Quagliariello
Journal: Annals of Oncology (2023)
2334P Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Authors: A. Weissferdt, C.H. Leung, B. Sepesi, W. Nassib William Junior, H. Lin, R. Mehran, D.L. Gibbons, A. Vaporciyan, J. Heymach, S. Swisher, J.J. Lee, T. Cascone, A. Pataer
Journal: Annals of Oncology (2023)
2303P Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Authors: F.W.F. Cerciello, P. Marchal, L. Bürgi, K. Samarasinghe, M. Martens, F. Ehrhart, C.T. Evelo, L. Lane
Journal: Annals of Oncology (2023)
8P Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation
Authors: M. Bequet-Romero, Y. Morera, F. Hernández-Bernal, C. Canaan-Haden, K-H. Selman-Housein, I. González-Moya, J. Sanchez-Ramirez, Y. Martín-Bauta, A. de la Torre-Santos, M. Ayala
Journal: Annals of Oncology (2023)
2307P Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Authors: N. Rameika, X. Zhang, L. Zhong, V. Rendo, S. Kundu, S. Nuciforo, I. Stoimenov, V. Ljungström, M.H. Heim, D. Globisch, T. Sjöblom
Journal: Annals of Oncology (2023)
CN52 Role of translational oncology research nurse (TORN) in improving patients (pts) adherence to microbiome research projects
Authors: A. Garcia Rodriguez, G. Castillo, I. Baraibar Argota, M. Sanchis, M. Sanz, I. Suarez, F. Salvà Ballabrera, F.J. Ros Montana, N. Saoudi Gonzalez, A.A. Valdivia, C. Perez Alonso, C. Rosales, A. Texidor, M. Rodriguez Castells, M. Marti Gallostra, A. Peñuelas Saiz, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2023)
2296P SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Authors: N. Maurea, I. Bisceglia, M. Iovine, A. Paccone, G. Palma, F. Bruzzese, A. Luciano, F. Florio, F. Zito Marino, R. Franco, V. Quagliariello
Journal: Annals of Oncology (2023)
CN26 Healthcare professionals’ perceptions on palliative care in onco-haematological area: Validation of the palliative care perception instrument
Authors: T. Buttiron Webber, G. Pegoraro, I. Lima, G. Catania, M. Calzolari, M. Zanini, L. Sasso, A. Bagnasco
Journal: Annals of Oncology (2023)
2304P A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Authors: E.J. Kang, Y. Yang, S. Lee, Y.J. Kim, S.M. Lim, M-J. Ahn, Y.J. Choi, Y. Lee, T.M. Kim, I. Kim, H. Ahn, H.C. Jeung, S.I. Lee, S.Y. Oh, W.K. Bae, K.H. Park, K.H. Lee
Journal: Annals of Oncology (2023)
17P Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Authors: R.A. Watson, O. Tong, B. Sun, C. Taylor, E. Jungkurth, S. Sijbesma, C. Ye, F. Matos Santo, M.R. Middleton, B.P. Fairfax
Journal: Annals of Oncology (2023)
18P Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Authors: A. Cavaliere, M. Macagno, F. Maione, V. Amodio, R. Chilà, S. Lamba, P.P. Vitiello, V. Pessei, N. Congiusta, A. Lorenzato, G. Germano, A. Bardelli, F. Di Nicolantonio
Journal: Annals of Oncology (2023)
CN17 Use of the ONCO'nect telemonitoring tool by socially deprived outpatients actively treated for a solid cancer: A retrospective quantitative and qualitative analysis of the Re'connect program
Authors: C. Boiteau, N. Alarcon, C. Joly, C. Fenioux, C. Ganter, C. Queval, S. Dutendas, I. Bartoszczyk, M. Bouayed, H. Ben Nadji, A. Briard, N. El Biad, C. Agius, C. Tournigand, E. Kempf
Journal: Annals of Oncology (2023)
2294P Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Authors: J. LoPiccolo, R. Collins, D.R. Koeller, A.C. Pollaci, E. Voligny, T. Nguyen, A.J. Pangilinan, X. Wang, L. Su, J. Lin, J.E. Garber, D.C. Christiani, S. Gusev, P.A. Jänne
Journal: Annals of Oncology (2023)
2000P Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Authors: J. Wu, J. Zhang, H. Sun, Y. Sun, Y. Ge, Q. Cheng, D. Wang, X. Wang, X. Fu, H. Sun, None J. li, A. Gao
Journal: Annals of Oncology (2023)
2320P Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
Authors: P. Horak, J. Becker, S. Blobner, D. Weber, S. Uhrig, J. Förster, A. Raveendran, A. Baude, J. Wagner, I. Poschke, I. Zörnig, M. Volkmar, M. Platten, D. Jäger, S. Fröhling, P. Chudasama, A. Riemer
Journal: Annals of Oncology (2023)
2255P Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Authors: B. Ricciuti, J.V. Alessi, X. Wang, F. Pecci, A. Di Federico, M. Gandhi, M. Makarem, L. Sholl, P.A. Jänne, C. Ambrogio, M.M. Awad
Journal: Annals of Oncology (2023)
97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Authors: C. Yoo, J.O. Park, K-P. Kim, J. Hyung, B-Y. Ryoo, J.Y. Hong, S.H. Shin, T.J. Song, D. Oh, None W. lee, B.J. Kwak, J.H. Lee, D.W. Hwang
Journal: Annals of Oncology (2023)